Cabaletta Bio

Performance

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching targeted cell therapies for autoimmune diseases. Through its Cabaletta Approach to B cell Ablation (CABA) platform, the company aims to deliver deep and durable, potentially curative T cell therapies. Headquartered in Philadelphia, PA, Cabaletta is advancing Rese-cel, a fully human CD19-CAR T cell therapy, across multiple autoimmune indications including lupus, myositis, systemic sclerosis, and generalized myasthenia gravis under its RESET trials. The company operates in the biopharmaceutical sector with a focus on immune-modulating cell therapies for autoimmune conditions.